Ainos Reports Second Quarter 2022 Financial Results
Ainos Reports Second Quarter 2022 Financial Results
SAN DIEGO, CA / ACCESSWIRE / August 15, 2022 /
加利福尼亚州圣迭戈/ACCESSWIRE/2022年8月15日/
$Ainos(AIMD.US)$ ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its unaudited financial results for the second quarter ended June 30, 2022.
$Ainos(AIMD.US)$Ainos是一家多元化的医疗科技公司，专注于开发新型的护理点检测、低剂量干扰素疗法和合成RNA驱动的预防性药物。该公司今天公布了截至2022年6月30日的第二季度未经审计的财务业绩。
Second Quarter 2022 Financial Highlights
2022年第二季度财务亮点
Revenues were US$636,627 in the second quarter of 2022, up 213.6% from US$202,992 in the same period of 2021.
Gross profit was US$317,664, representing a gross margin of 49.9% in the second quarter of 2022.
2022年第二季度的收入为636,627美元，比2021年同期的202,992美元增长了213.6。
2022年第二季度的毛利为317,664美元，毛利率为49.9%。
Chun-Hsien Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "We are pleased to announce our first quarterly results as a Nasdaq-listed company with significant year-over-year revenue growth and promising operational milestones. This has been a momentous year for us, our partners, and our shareholders. Receiving approval for our COVID-19 Antigen Self-Test to be sold in Taiwan and the positive preclinical study results for our VELDONA interferon formulation demonstrates the strength of our product portfolio as we strive to fulfill our mission to develop a telehealth-enabled future for precision medicine. Our Nasdaq uplisting is an exciting new chapter in our development, providing us with wider access to capital, raising our corporate profile, and positioning us to deliver greater and more sustainable value for our shareholders. With our low-cost operations and cutting-edge technology, the building blocks for our future growth as a diversified medtech company are firmly in place."
爱诺士董事局主席兼首席执行官蔡俊贤表示：“我们很高兴宣布作为纳斯达克上市公司的首个季度业绩，营收较上年同期有显著增长，并有望实现各项运营里程碑。对于我们、我们的合作伙伴和我们的股东来说，这是重要的一年。我们的新冠肺炎抗原自我检测获准在台湾销售，我们的VELDONA干扰素配方的临床前研究结果呈阳性，这表明了我们产品组合的实力，因为我们正在努力履行我们的使命，为精确医学开发一个支持远程医疗的未来。纳斯达克的崛起揭开了我们发展的激动人心的新篇章，为我们提供了更广泛的资金渠道，提升了我们的企业形象，并使我们定位于为股东提供更大、更可持续的价值。凭借我们的低成本运营和尖端技术，我们作为一家多元化的医疗科技公司未来增长的基石已经牢牢到位。“
Hui-Lan Wu, Chief Financial Officer of Ainos, commented, "Increased sales of our COVID-19 Antigen Rapid Test Kits during the second quarter drove robust year-over-year 213.6% top-line growth. With the additional capital provided by our recent uplisting, we are well positioned to meet our product development targets, capture emerging market opportunities, and generate long-term growth for our shareholders. Looking ahead, we will continue to commercialize our medical device pipeline while expanding and strengthening our innovative product portfolio."
爱诺斯首席财务官吴慧兰表示：“第二季度，我们的COVID-19抗原快速检测试剂盒销量增加，推动营收同比强劲增长213.6%。随着我们最近的崛起提供了额外的资本，我们处于有利地位，能够实现我们的产品开发目标，抓住新兴市场机遇，为我们的股东带来长期增长。展望未来，我们将继续将我们的医疗器械生产线商业化，同时扩大和加强我们的创新产品组合。”
Second Quarter 2022 Financial Results
2022年第二季度财务业绩
Revenues
收入
Revenues increased by 213.6% to US$636,627 in the second quarter of 2022 from US$202,992 in the same period of 2021, mainly driven by the increased product sales of the Ainos COVID-19 Antigen Rapid Test Kits in Taiwan.
收入由2021年同期的202,992美元上升至2022年第二季的636,627美元，增幅达213.6%，主要是由于Ainos CoVID-19抗原快速检测试剂盒在台湾的产品销售增加所致。
Cost of Revenues
收入成本
Cost of revenues was US$318,963 in the second quarter of 2022, compared with US$69,508 in the same period of 2021, mainly driven by the increase in associated cost of product sales of the Ainos COVID-19 Antigen Rapid Test Kits.
2022年第二季度的收入成本为318,963美元，而2021年同期为69,508美元，这主要是由于Ainos COVID-19抗原快速检测试剂盒的相关产品销售成本增加所致。
Gross Profit
毛利
Gross profit was US$317,664, representing 49.9% of sales in the second quarter of 2022.
毛利润为317,664美元，占2022年第二季度销售额的49.9%。
Total Operating Expenses
总运营费用
Total operating expenses increased by 163.0% to US$2,261,960 in the second quarter of 2022 from US$860,030 in the same period of 2021, mainly attributable to increased research and development expenses. The increase in research and development expenses reflects the Company's ongoing investments in research and development, in line with its product development plans.
总营运开支由2021年同期的860,030美元上升至2022年第二季的2,261,960美元，增幅达163.0%，主要是由于研发开支增加所致。研究和开发费用的增加反映了公司根据其产品开发计划对研究和开发进行的持续投资。
Net Loss
净亏损
Net loss attributable to common stock shareholders was US$1,954,032 in the second quarter of 2022, compared with US$749,774 in the same period of 2021.
2022年第二季度普通股股东应占净亏损为1,954,032美元，而2021年同期为749,774美元。
Balance Sheet
资产负债表
As of June 30, 2022, the Company had cash and cash equivalents of US$1,753,877, compared with US$1,751,499 as of December 31, 2021.
截至2022年6月30日，公司的现金及现金等价物为1,753,877美元，而截至2021年12月31日的现金及现金等价物为1,751,499美元。
Recent Developments
最新发展动态
On June 21, 2022, the Company announced it has begun marketing the Ainos COVID-19 Antigen Self-Test Kit under an Emergency Use Authorization that was issued by the Taiwan Food and Drug Administration on June 13, 2022 to Taiwan Carbon Nano Technology Corporation, the manufacturer and product co-developer of the test in conjunction with Ainos. Ainos is the exclusive master sales and marketing agent for the COVID-19 Antigen Self-Test Kit.
2022年6月21日，该公司宣布，根据台湾食品药品监督管理局于2022年6月13日向台湾碳纳米科技公司发出的紧急使用授权，已开始销售Ainos新冠肺炎抗原自检试剂盒。台湾碳纳米科技公司是Ainos联合测试的制造商和产品联合开发商。艾诺斯是新冠肺炎抗原自检试剂盒的独家销售总代理。
On June 27, 2022, the Company announced the topline results from its COVID-19 antiviral efficacy study in hamsters. The available results show that its low-dose oral interferon alpha formulation, VELDONA, has a protective effect on lungs infected with the SARS-CoV-2 virus by regulating the immune response, thus expediting recovery of infected animals. The Company is preparing application documents for U.S. FDA Phase 2/3 clinical trials.
2022年6月27日，该公司公布了其新冠肺炎对仓鼠的抗病毒疗效研究结果。现有结果表明，其低剂量口服干扰素α制剂VELDONA通过调节免疫反应，对感染SARS-CoV-2病毒的肺部具有保护作用，从而加快受感染动物的康复。该公司正在准备美国FDA第2/3期临床试验的申请文件。
On August 12, 2022, the Company announced the closing of its previously announced underwritten public offering of 780,000 units at a public offering price of $4.25 per unit. Each unit issued in the offering consisted of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $4.25. The common stock and warrants were immediately separable and were issued separately. The common stock and warrants began trading on the Nasdaq Capital Market on August 9, 2022, under the symbols "AIMD" and "AIMDW," respectively. Ainos received gross proceeds of approximately $3.3 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
2022年8月12日，公司宣布结束此前宣布的78万个单位的包销公开发行，公开发行价为每单位4.25美元。此次发行的每个单位包括一股普通股和一股认股权证，以4.25美元的行使价购买一股普通股。普通股和认股权证可以立即分开，并单独发行。该普通股和权证于2022年8月9日在纳斯达克资本市场开始交易，代码分别为AIMD和AIMDW。在扣除承销折扣和佣金以及其他估计的发行费用之前，Ainos获得了约330万美元的毛收入。
About Ainos, Inc.
关于Ainos公司
Headquartered in San Diego, California, Ainos, Inc. (f/k/a Amarillo Biosciences, Inc.) is a diversified medtech company engaged in developing innovative medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. In addition to its proprietary therapeutics using low-dose non-injectable interferon, Ainos is committed to developing a comprehensive healthcare business portfolio encompassing medical devices and consumer healthcare products. While prioritizing the commercialization of medical devices as part of its diversification strategy, Ainos has also expanded its product portfolio to include Volatile Organic Compounds (VOC) and COVID-19 POCTs. Leveraging its patents related to VOC technologies and three issued patents for COVID-19 POCT products, the Company seeks to expedite the commercialization of its medical device pipeline, beginning with Ainos-branded COVID-19 POCT product candidates.
总部设在加利福尼亚州圣地亚哥的Ainos，Inc.(法国/法国/a Amarillo生物科学公司)是一家多元化的医疗科技公司，致力于开发创新的医疗技术，用于护理点检测和针对各种疾病适应症的安全和新颖的医疗治疗。除了使用低剂量非注射干扰素的专利疗法外，Ainos还致力于开发涵盖医疗设备和消费者保健产品的全面医疗保健业务组合。在将医疗器械商业化作为其多元化战略的一部分作为优先事项的同时，Ainos还扩大了其产品组合，包括挥发性有机化合物(VOC)和新冠肺炎POCT。利用其与VOC技术相关的专利和三项已颁发的新冠肺炎POCT产品专利，该公司寻求加快其医疗器械生产线的商业化进程，首先是Ainos品牌的新冠肺炎POCT候选产品。
Forward-Looking Statements
前瞻性陈述
This press release contains 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict," "project," 'target," "future," "seek," "likely," "strategy," "may," "should," "will," and similar references to future periods. Forward-looking statements are based only on our current beliefs, expectations, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements.
本新闻稿包含符合1995年美国私人证券诉讼改革法安全港条款的“前瞻性陈述”。前瞻性陈述可以通过诸如“预期”、“相信”、“估计”、“预期”、“打算”、“计划”、“预测”、“项目”、“目标”、“未来”、“寻求”、“可能”、“战略”、“可能”、“应该”、“将会”以及对未来时期的类似提法来识别。前瞻性陈述仅基于我们当前的信念、预期和假设。前瞻性陈述会受到固有的不确定性、风险和环境变化的影响，这些不确定性、风险和变化很难预测，其中许多是我们无法控制的。我们的实际结果可能与前瞻性陈述中指出的大不相同。
Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, the following: the cost of production and sales potential of the planned drug treatments announced in this press release; the impact of final approvals from the U.S. Food and Drug Administration (the "FDA") or other regulatory bodies for the planned drug treatments including the availability of emergency use authorization; the Company's limited cash and history of losses; the Company's ability to achieve profitability; intense competition and rapidly advancing technology in the Company's industry that may outpace its technology; customer demand for the products and services the Company develops; the impact of competitive or alternative products, technologies and pricing; the Company's ability to manufacture any products it develops; general economic conditions and events and the impact they may have on the Company and its potential customers, including but not limited to the impact of Covid-19; the Company's ability to obtain adequate financing in the future; the impact of promulgation and implementation of regulations by the World Health Organization, the FDA and by other governmental authorities with functions similar to those of the FDA on the Company's operations and technologies; lawsuits and other claims by third parties or investigations by various regulatory agencies governing the Company's operations; the Company's ability to secure regulatory approvals for its products; and our success in managing the risks involved in the foregoing items. Readers should also review the risks and uncertainties listed in our Annual Report on Form 10-K for the year ended December 31, 2021 and other reports we file with the U.S. Securities and Exchange Commission.
可能导致我们的实际结果与前瞻性陈述中显示的结果大不相同的重要因素包括但不限于：本新闻稿中宣布的计划药物治疗的生产成本和销售潜力；美国食品和药物管理局(FDA)或其他监管机构对计划药物治疗的最终批准的影响，包括紧急使用授权的可用性；公司有限的现金和历史亏损；公司实现盈利的能力；公司行业的激烈竞争和快速进步的技术可能超过其技术；客户对公司开发的产品和服务的需求；竞争性或替代产品、技术和定价的影响；公司生产其开发的任何产品的能力；总体经济状况和事件及其可能对公司及其潜在客户造成的影响，包括但不限于“新冠肺炎”的影响；公司未来获得充足资金的能力；世界卫生组织、食品和药物管理局以及其他职能类似于食品和药物管理局的政府机构颁布和实施法规对公司业务和技术的影响；第三方的诉讼和其他索赔或管理公司运营的各种监管机构的调查；公司确保其产品获得监管部门批准的能力；以及我们成功地管理上述项目中涉及的风险。读者还应查阅我们截至2021年12月31日的Form 10-K年度报告以及我们提交给美国证券交易委员会的其他报告中列出的风险和不确定性。
Any forward-looking statement made by us in this press release speaks only as of the date on which such statement is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
我们在本新闻稿中所作的任何前瞻性声明仅限于该声明发表之日。我们没有义务公开更新任何可能不时作出的前瞻性陈述，无论是书面的还是口头的，无论是新信息、未来发展还是其他情况。
Investor Relations Contact
ICR, LLC
Robin Yang
Tel: +1 646-224-6971
Email: Ainos.IR@icrinc.com
投资者关系联系人
ICR，LLC
杨彦宏
电话：+1646-224-6971
电子邮件：Ainos.IR@icrinc.com
Ainos, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
Ainos公司
简明综合 营运说明书
(未经审计)
| Three months ended June 30, | Six months ended June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
Revenues |
$ | 636,627 | $ | 202,992 | $ | 723,828 | $ | 205,113 | ||||||||
Cost of revenues |
(318,963 | ) | (69,508 | ) | (360,042 | ) | (70,757 | ) | ||||||||
Gross profit |
317,664 | 133,484 | 363,786 | 134,356 | ||||||||||||
Operating expenses |
||||||||||||||||
Research and development expenses |
1,634,856 | - | 3,212,310 | - | ||||||||||||
Selling, general and administrative expenses |
627,104 | 860,030 | 1,178,834 | 1,383,011 | ||||||||||||
Total operating expenses |
2,261,960 | 860,030 | 4,391,144 | 1,383,011 | ||||||||||||
Operating loss |
(1,944,296 | ) | (726,546 | ) | (4,027,358 | ) | (1,248,655 | ) | ||||||||
Non-operating income and expenses, net |
||||||||||||||||
Loss on sale of fixed assets |
- | (2,247 | ) | - | (2,247 | ) | ||||||||||
Interest expense, net |
(18,796 | ) | (20,981 | ) | (35,483 | ) | (32,879 | ) | ||||||||
Other income, net |
9,060 | - | 8,914 | - | ||||||||||||
Total non-operating income and expenses, net |
(9,736 | ) | (23,228 | ) | (26,569 | ) | (35,126 | ) | ||||||||
Net loss |
(1,954,032 | ) | (749,774 | ) | (4,053,927 | ) | (1,283,781 | ) | ||||||||
Basic and diluted net loss per average share available to common shareholders |
$ | (0.01 | ) | $ | (0.01 | ) | $ | (0.03 | ) | $ | (0.02 | ) | ||||
Weighted average common shares outstanding - basic and diluted |
144,379,308 | 124,644,759 | 144,379,308 | 83,583,583 | ||||||||||||
| 截至6月30日的三个月， | 截至6月30日的六个月， | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
收入 |
$ | 636,627 | $ | 202,992 | $ | 723,828 | $ | 205,113 | ||||||||
收入成本 |
(318,963 | ) | (69,508 | ) | (360,042 | ) | (70,757 | ) | ||||||||
毛利 |
317,664 | 133,484 | 363,786 | 134,356 | ||||||||||||
运营费用 |
||||||||||||||||
研发费用 |
1,634,856 | - | 3,212,310 | - | ||||||||||||
销售、一般和行政费用 |
627,104 | 860,030 | 1,178,834 | 1,383,011 | ||||||||||||
总运营费用 |
2,261,960 | 860,030 | 4,391,144 | 1,383,011 | ||||||||||||
营业亏损 |
(1,944,296 | ) | (726,546 | ) | (4,027,358 | ) | (1,248,655 | ) | ||||||||
营业外收入和费用，净额 |
||||||||||||||||
固定资产销售损失 |
- | (2,247 | ) | - | (2,247 | ) | ||||||||||
利息支出，净额 |
(18,796 | ) | (20,981 | ) | (35,483 | ) | (32,879 | ) | ||||||||
其他收入，净额 |
9,060 | - | 8,914 | - | ||||||||||||
营业外收支合计(净额) |
(9,736 | ) | (23,228 | ) | (26,569 | ) | (35,126 | ) | ||||||||
净亏损 |
(1,954,032 | ) | (749,774 | ) | (4,053,927 | ) | (1,283,781 | ) | ||||||||
普通股股东每股基本和稀释后每股净亏损 |
$ | (0.01 | ) | $ | (0.01 | ) | $ | (0.03 | ) | $ | (0.02 | ) | ||||
加权平均已发行普通股-基本普通股和稀释普通股 |
144,379,308 | 124,644,759 | 144,379,308 | 83,583,583 | ||||||||||||
Ainos, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
Ainos公司
简明综合资产负债表
(未经审计)
| June 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
Assets |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | 1,753,877 | $ | 1,751,499 | ||||
Inventory |
670,507 | - | ||||||
Other current assets |
1,274,512 | 466,198 | ||||||
Total current assets |
3,698,896 | 2,217,697 | ||||||
Intangible assets, net |
35,086,424 | 37,329,191 | ||||||
Property and equipment, net |
1,503,025 | 1,187,702 | ||||||
Other assets |
124,697 | 87,571 | ||||||
Total assets |
$ | 40,413,042 | $ | 40,822,161 | ||||
Liabilities and Stockholders' Equity |
||||||||
Current liabilities: |
||||||||
Convertible notes payable |
$ | 3,376,526 | $ | 3,376,526 | ||||
Notes payable |
1,013,405 | 213,405 | ||||||
Accrued expenses and others current liabilities |
2,598,468 | 1,004,868 | ||||||
Payables - related party |
- | 26,000,000 | ||||||
Total current liabilities |
6,988,399 | 30,594,799 | ||||||
Long term liabilities: |
||||||||
Convertible notes payable - noncurrent |
27,400,000 | - | ||||||
Operating lease liabilities - noncurrent |
18,323 | 30,255 | ||||||
Total long term liabilities |
27,418,323 | 30,255 | ||||||
Total liabilities |
34,406,722 | 30,625,054 | ||||||
Stockholders' equity |
||||||||
Preferred stock, $0.01 par value; 10,000,000 shares |
||||||||
authorized; none issued |
||||||||
Common stock, $0.01 par value; 300,000,000 shares |
||||||||
authorized as of June 30, 2022 and December 31, |
||||||||
2021; 144,379,308 shares issued and outstanding as |
||||||||
of June 30, 2022 and December 31, 2021 |
1,443,793 | 1,443,793 | ||||||
Additional paid-in capital |
18,943,316 | 18,856,430 | ||||||
Accumulated deficit |
(14,162,843 | ) | (10,108,916 | ) | ||||
Translation adjustment |
(217,946 | ) | 5,800 | |||||
Total stockholders' equity |
6,006,320 | 10,197,107 | ||||||
Total liabilities and stockholders' equity |
$ | 40,413,042 | $ | 40,822,161 | ||||
| 6月30日， | 十二月三十一日， | |||||||
| 2022 | 2021 | |||||||
资产 |
||||||||
流动资产： |
||||||||
现金和现金等价物 |
$ | 1,753,877 | $ | 1,751,499 | ||||
库存 |
670,507 | - | ||||||
其他流动资产 |
1,274,512 | 466,198 | ||||||
流动资产总额 |
3,698,896 | 2,217,697 | ||||||
无形资产，净额 |
35,086,424 | 37,329,191 | ||||||
财产和设备，净额 |
1,503,025 | 1,187,702 | ||||||
其他资产 |
124,697 | 87,571 | ||||||
总资产 |
$ | 40,413,042 | $ | 40,822,161 | ||||
负债与股东权益 |
||||||||
流动负债： |
||||||||
可转换应付票据 |
$ | 3,376,526 | $ | 3,376,526 | ||||
应付票据 |
1,013,405 | 213,405 | ||||||
应计费用和其他流动负债 |
2,598,468 | 1,004,868 | ||||||
应付款关联方 |
- | 26,000,000 | ||||||
流动负债总额 |
6,988,399 | 30,594,799 | ||||||
长期负债： |
||||||||
可转换应付票据-非流动票据 |
27,400,000 | - | ||||||
经营租赁负债--非流动负债 |
18,323 | 30,255 | ||||||
长期负债总额 |
27,418,323 | 30,255 | ||||||
总负债 |
34,406,722 | 30,625,054 | ||||||
股东权益 |
||||||||
优先股，面值0.01美元；1000万股 |
||||||||
已授权；未颁发 |
||||||||
普通股，面值0.01美元；300,000,000股 |
||||||||
自2022年6月30日和12月31日起授权， |
||||||||
2021年；已发行和已发行的144,379,308股 |
||||||||
2022年6月30日和2021年12月31日 |
1,443,793 | 1,443,793 | ||||||
额外实收资本 |
18,943,316 | 18,856,430 | ||||||
累计赤字 |
(14,162,843 | ) | (10,108,916 | ) | ||||
翻译调整 |
(217,946 | ) | 5,800 | |||||
股东权益总额 |
6,006,320 | 10,197,107 | ||||||
总负债和股东权益 |
$ | 40,413,042 | $ | 40,822,161 | ||||
SOURCE: Ainos, Inc.
资料来源：Ainos公司
View source version on accesswire.com:
在accesswire.com上查看源代码版本：